Phospholamban Ablation Using CRISPR/Cas9 System Improves Mortality in a Murine Heart Failure Model

Open Access

Peer-reviewed

Research Article

Manami Kaneko ,

* E-mail: manami.kaneko@takeda.com

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Kentarou Hashikami,

Affiliation Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Satoshi Yamamoto,

Affiliation Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Hirokazu Matsumoto,

Affiliation Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Tomoyuki Nishimoto

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯

Reader Comments (0)

Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Genetically modified animals
Is the Subject Area "Genetically modified animals" applicable to this article?

Thanks for your feedback.
Homozygosity
Is the Subject Area "Homozygosity" applicable to this article?

Thanks for your feedback.
Polymerase chain reaction
Is the Subject Area "Polymerase chain reaction" applicable to this article?

Thanks for your feedback.
Body weight
Is the Subject Area "Body weight" applicable to this article?

Thanks for your feedback.
Heart failure
Is the Subject Area "Heart failure" applicable to this article?

Thanks for your feedback.
Cardiovascular physiology
Is the Subject Area "Cardiovascular physiology" applicable to this article?

Thanks for your feedback.
Blood pressure
Is the Subject Area "Blood pressure" applicable to this article?

Thanks for your feedback.